

Gerasimos Aravantinos

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3403957/publications.pdf>

Version: 2024-02-01

90
papers

4,140
citations

186209

28
h-index

128225

60
g-index

93
all docs

93
docs citations

93
times ranked

7385
citing authors

#	ARTICLE	IF	CITATIONS
1	Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. <i>Lancet</i> , The, 2019, 394, 1915-1928.	6.3	1,804
2	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. <i>Nature Genetics</i> , 2017, 49, 680-691.	9.4	356
3	Advanced stage mucinous epithelial ovarian cancer: The Hellenic Cooperative Oncology Group experience. <i>Gynecologic Oncology</i> , 2005, 97, 436-441.	0.6	133
4	Anti-PD1/PDL1 induced psoriasis. <i>Current Problems in Cancer</i> , 2017, 41, 407-412.	1.0	90
5	Oral estramustine and oral etoposide for hormone-refractory prostate cancer. <i>Urology</i> , 1997, 50, 754-758.	0.5	78
6	Dose selection trial of metronomic oral vinorelbine monotherapy in patients with metastatic cancer: a hellenic cooperative oncology group clinical translational study. <i>BMC Cancer</i> , 2013, 13, 263.	1.1	68
7	Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 862-876.	5.1	68
8	Docetaxel and Gemcitabine in Anthracycline-Resistant Advanced Breast Cancer: A Hellenic Cooperative Oncology Group Phase II Study. <i>Cancer Investigation</i> , 2000, 18, 503-509.	0.6	57
9	Tumors with high-density tumor infiltrating lymphocytes constitute a favorable entity in breast cancer: a pooled analysis of four prospective adjuvant trials. <i>Oncotarget</i> , 2016, 7, 5074-5087.	0.8	54
10	Bevacizumab in combination with chemotherapy for the treatment of advanced ovarian cancer: a systematic review. <i>Journal of Ovarian Research</i> , 2014, 7, 57.	1.3	52
11	Improved Outcome of High-Risk Early HER2 Positive Breast Cancer With High CXCL13-CXCR5 Messenger RNA Expression. <i>Clinical Breast Cancer</i> , 2012, 12, 183-193.	1.1	49
12	Oxaliplatin and Irinotecan plus Granulocyte-Colony Stimulating Factor as Third-Line Treatment in Relapsed or Cisplatin-Refractory Germ-Cell Tumor Patients: A Phase II Study. <i>European Urology</i> , 2004, 46, 216-221.	0.9	48
13	HER2 and TOP2A in high-risk early breast cancer patients treated with adjuvant epirubicin-based dose-dense sequential chemotherapy. <i>Journal of Translational Medicine</i> , 2012, 10, 10.	1.8	46
14	A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 791-803.	1.1	46
15	Oxaliplatin for Pretreated Patients with Advanced or Metastatic Pancreatic Cancer: A Multicenter Phase II Study. <i>Cancer Investigation</i> , 2005, 23, 9-12.	0.6	45
16	Mutational Analysis of Circulating Tumor Cells from Colorectal Cancer Patients and Correlation with Primary Tumor Tissue. <i>PLoS ONE</i> , 2015, 10, e0123902.	1.1	45
17	Gemcitabine versus Gemcitabine+Carboplatin for Patients with Advanced Non-small Cell Lung Cancer and a Performance Status of 2: A Prospective Randomized Phase II Study of the Hellenic Cooperative Oncology Group. <i>Journal of Thoracic Oncology</i> , 2007, 2, 135-140.	0.5	44
18	A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2010, 8, 3.	2.3	42

#	ARTICLE	IF	CITATIONS
19	A randomized phase III trial of adjuvant chemotherapy with irinotecan, leucovorin and fluorouracil versus leucovorin and fluorouracil for stage II and III colon cancer: A Hellenic Cooperative Oncology Group study. <i>BMC Medicine</i> , 2011, 9, 10.	2.3	41
20	Assessment of Progression-Free Survival as a Surrogate End Point of Overall Survival in First-Line Treatment of Ovarian Cancer. <i>JAMA Network Open</i> , 2020, 3, e1918939.	2.8	40
21	Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients. <i>PLoS ONE</i> , 2019, 14, e0226853.	1.1	39
22	Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients. <i>European Journal of Cancer</i> , 2017, 82, 237-246.	1.3	38
23	Palliative chemotherapy in elderly patients with common metastatic malignancies: A Hellenic Cooperative Oncology Group registry analysis of management, outcome and clinical benefit predictors. <i>Critical Reviews in Oncology/Hematology</i> , 2008, 66, 237-247.	2.0	37
24	Caspase 8 and caspase 9 gene polymorphisms and susceptibility to gastric cancer. <i>Gastric Cancer</i> , 2011, 14, 317-321.	2.7	34
25	Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers. <i>Cancer Genomics and Proteomics</i> , 2017, 14, 181-195.	1.0	30
26	MMP9 but Not EGFR, MET, ERCC1, P16, and P-53 Is Associated with Response to Concomitant Radiotherapy, Cetuximab, and Weekly Cisplatin in Patients with Locally Advanced Head and Neck Cancer. <i>Journal of Oncology</i> , 2009, 2009, 1-17.	0.6	29
27	<i>KRAS</i> , <i>NRAS</i> and <i>BRAF</i> mutations in Greek and Romanian patients with colorectal cancer: a cohort study. <i>BMJ Open</i> , 2014, 4, e004652.	0.8	29
28	Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>PLoS ONE</i> , 2015, 10, e0140293.	1.1	29
29	Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses. <i>International Journal of Oncology</i> , 2009, 35, 401-16.	1.4	29
30	Prevalence of BRCA1 Mutations in Familial and Sporadic Greek Ovarian Cancer Cases. <i>PLoS ONE</i> , 2013, 8, e58182.	1.1	27
31	Pegfilgrastim Administered on the Same Day with Dose-Dense Adjuvant Chemotherapy for Breast Cancer Is Associated with a Higher Incidence of Febrile Neutropenia as Compared to Conventional Growth Factor Support: Matched Case-Control Study of the Hellenic Cooperative Oncology Group. <i>Oncology</i> , 2009, 77, 107-112.	0.9	26
32	Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients. <i>Oncology Letters</i> , 2015, 10, 2176-2184.	0.8	26
33	Oxaliplatin as First-Line Treatment in Inoperable Biliary Tract Carcinoma. <i>Oncology</i> , 2006, 70, 280-284.	0.9	25
34	MYC copy gain, chromosomal instability and PI3K activation as potential markers of unfavourable outcome in trastuzumab-treated patients with metastatic breast cancer. <i>Journal of Translational Medicine</i> , 2016, 14, 136.	1.8	25
35	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. <i>European Journal of Human Genetics</i> , 2022, 30, 349-362.	1.4	23
36	Immune Response Gene Expression in Colorectal Cancer Carries Distinct Prognostic Implications According to Tissue, Stage and Site: A Prospective Retrospective Translational Study in the Context of a Hellenic Cooperative Oncology Group Randomised Trial. <i>PLoS ONE</i> , 2015, 10, e0124612.	1.1	20

#	ARTICLE	IF	CITATIONS
37	Carboplatin and Paclitaxel versus Cisplatin, Paclitaxel and Doxorubicin for first-line chemotherapy of Advanced Ovarian Cancer: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>European Journal of Cancer</i> , 2008, 44, 2169-2177.	1.3	19
38	Identification of Methylation Profiles of Cancer-related Genes in Circulating Tumor Cells Population. <i>Anticancer Research</i> , 2017, 37, 1105-1112.	0.5	18
39	Gemcitabine plus pegylated liposomal doxorubicin in patients with advanced epithelial ovarian cancer resistant/refractory to platinum and/or taxanes. A HeCOG phase II study. <i>Anticancer Research</i> , 2005, 25, 3103-8.	0.5	18
40	Dose-Dense Adjuvant Chemotherapy with Epirubicin Monotherapy in Patients with Operable Breast Cancer and ≥10 Positive Axillary Lymph Nodes. <i>Oncology</i> , 1998, 55, 508-512.	0.9	17
41	Safety and Tolerability of Anthracycline-Containing Adjuvant Chemotherapy in Elderly High-Risk Breast Cancer Patients. <i>Clinical Breast Cancer</i> , 2016, 16, 291-298.e3.	1.1	17
42	Evaluation of the Prognostic Value of RANK, OPG, and RANKL mRNA Expression in Early Breast Cancer Patients Treated with Anthracycline-Based Adjuvant Chemotherapy. <i>Translational Oncology</i> , 2017, 10, 589-598.	1.7	17
43	Evaluation of the Prognostic and Predictive Value of HER-1/EGFR in Breast Cancer Patients Participating in a Randomized Study with Dose-Dense Sequential Adjuvant Chemotherapy. <i>Oncology</i> , 2007, 72, 388-396.	0.9	16
44	Effects of TP53 and PIK3CA mutations in early breast cancer: a matter of co-mutation and tumor-infiltrating lymphocytes. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 307-321.	1.1	16
45	Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. <i>Journal of Translational Medicine</i> , 2015, 13, 171.	1.8	15
46	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. <i>Oncotarget</i> , 2018, 9, 35623-35638.	0.8	15
47	Grade-dependent effects on cell cycle progression and apoptosis in response to doxorubicin in human bladder cancer cell lines. <i>International Journal of Oncology</i> , 2009, 34, 137-60.	1.4	15
48	Effects of stromal cell-derived factor-1 and survivin gene polymorphisms on gastric cancer risk. <i>Molecular Medicine Reports</i> , 2013, 7, 887-892.	1.1	14
49	Association of osteopontin with specific prognostic factors and survival in adjuvant breast cancer trials of the Hellenic Cooperative Oncology Group. <i>Journal of Translational Medicine</i> , 2017, 15, 30.	1.8	14
50	Protein expression patterns of cell cycle regulators in operable breast cancer. <i>PLoS ONE</i> , 2017, 12, e0180489.	1.1	14
51	Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: A Hellenic Cooperative Oncology Group (HeCOG) study. <i>Oncology Reports</i> , 2011, 27, 216-24.	1.2	12
52	Aims, design and methods of a case-control study for the assessment of the role of dietary habits, eating behaviors and environmental factors, on the development of breast cancer. <i>Maturitas</i> , 2013, 74, 31-36.	1.0	12
53	AMALTHEA: Prospective, Single-Arm Study of the Hellenic Cooperative Oncology Group (HeCOG) Evaluating Efficacy and Safety of First-Line FOLFIRI+ Aflibercept for 6 Months Followed by Aflibercept Maintenance in Patients With Metastatic Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2018, 17, e631-e637.	1.0	12
54	Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer. <i>Cancer Biomarkers</i> , 2019, 25, 213-221.	0.8	12

#	ARTICLE	IF	CITATIONS
55	Thymidylate synthase inhibition induces p53-dependent and p53-independent apoptotic responses in human urinary bladder cancer cells. <i>Journal of Cancer Research and Clinical Oncology</i> , 2011, 137, 359-374.	1.2	10
56	Fluoropyrimidine-induced toxicity and DPD deficiency.. A case report of early onset, lethal capecitabine-induced toxicity and mini review of the literature. Uridine triacetate: Efficacy and safety as an antidote. Is it accessible outside USA?. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 747-753.	0.5	10
57	Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma. <i>Cancers</i> , 2021, 13, 198.	1.7	10
58	Prognostic Subcellular Notch2, Notch3 and Jagged1 Localization Patterns in Early Triple-negative Breast Cancer. <i>Anticancer Research</i> , 2017, 37, 2334.	0.5	10
59	A Phase III Study of 5-Fluorouracil Versus 5-Fluorouracil Plus Interferon Alpha 2b Versus 5-Fluorouracil Plus Leucovorin in Patients With Advanced Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2002, 25, 23-30.	0.6	9
60	Impact of Dose Reductions, Delays Between Chemotherapy Cycles, and/or Shorter Courses of Adjuvant Chemotherapy in Stage II and III Colorectal Cancer Patients: a Single-Center Retrospective Study. <i>Journal of Gastrointestinal Cancer</i> , 2015, 46, 343-349.	0.6	9
61	The Prognostic Value of the Immunohistochemical Expression of Phosphorylated RB and p16 Proteins in Association with Cyclin D1 and the p53 Pathway in a Large Cohort of Patients with Breast Cancer Treated with Taxane-based Adjuvant Chemotherapy. <i>Anticancer Research</i> , 2017, 37, 2947-2957.	0.5	9
62	Megestrol Acetate in Cancer Patients with Anorexia and Weight Loss a Hellenic co-operative oncology group (HeCOG) study. <i>Acta Oncologica</i> , 1993, 32, 37-41.	0.8	8
63	Tumor Infiltrating Lymphocytes Affect the Outcome of Patients with Operable Triple-Negative Breast Cancer in Combination with Mutated Amino Acid Classes. <i>PLoS ONE</i> , 2016, 11, e0163138.	1.1	8
64	Correlation of MYC Gene and Protein Status With Breast Cancer Subtypes and Outcome of Patients Treated With Anthracycline-Based Adjuvant Chemotherapy. Pooled Analysis of 2 Hellenic Cooperative Group Phase III Trials. <i>Clinical Breast Cancer</i> , 2018, 18, 53-62.e3.	1.1	8
65	Comparison of HER2 Detection Methods Between Central and Regional Laboratories in Greece. <i>Clinical Breast Cancer</i> , 2007, 7, 784-790.	1.1	7
66	Gemcitabine and pegylated liposomal doxorubicin alternating with cisplatin plus cyclophosphamide in platinum refractory/resistant, paclitaxel-pretreated, ovarian carcinoma. <i>Gynecologic Oncology</i> , 2008, 108, 47-52.	0.6	7
67	MiR-218 and miR-100 polymorphisms as markers of irinotecan-based chemotherapy response in metastatic colorectal cancer. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1871-1877.	1.0	7
68	The combination of estramustine, vinorelbine, and mitoxantrone in hormone-refractory prostate cancer: A Phase II feasibility study conducted by the Hellenic Cooperative Oncology Group. <i>Urology</i> , 2005, 66, 382-385.	0.5	6
69	Adjuvant Dose-Dense Sequential Chemotherapy with Epirubicin, CMF and Weekly Paclitaxel in Patients with Resected High-Risk Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Study. <i>Cancer Investigation</i> , 2008, 26, 491-498.	0.6	6
70	PAI-1 and HER2 interaction in advanced breast cancer disease: evidence for added benefit from trastuzumab in HER2-negative patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 75, 1289-1301.	1.1	6
71	Pegylated liposomal doxorubicin hydrochloride (PLD) and paclitaxel in recurrent or metastatic head and neck carcinoma: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (HeCOG). <i>Anti-Cancer Drugs</i> , 2004, 15, 479-487.	0.7	5
72	Prognostic Impact of Src, CDKN1B, and JAK2 Expression in Metastatic Breast Cancer Patients Treated with Trastuzumab. <i>Translational Oncology</i> , 2019, 12, 739-748.	1.7	5

#	ARTICLE	IF	CITATIONS
73	E-Selectin S128R Gene Polymorphism in Gastric Cancer. <i>International Journal of Biological Markers</i> , 2013, 28, 38-42.	0.7	4
74	The combination of bevacizumab/temsirolimus after first-line anti-VEGF therapy in advanced renal-cell carcinoma: a clinical and biomarker study. <i>International Journal of Clinical Oncology</i> , 2019, 24, 411-419.	1.0	4
75	Androgen Receptor and PIM1 Expression in Tumor Tissue of Patients With Triple-negative Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2021, 18, 147-156.	1.0	4
76	Comparison of the Ability of Different Clinical Treatment Scores to Estimate Prognosis in High-Risk Early Breast Cancer Patients: A Hellenic Cooperative Oncology Group Study. <i>PLoS ONE</i> , 2016, 11, e0164013.	1.1	4
77	Prediction of response to combination chemotherapy with irinotecan in Greek patients with metastatic colorectal cancer. <i>Journal of Cancer Research and Therapeutics</i> , 2016, 12, 193.	0.3	4
78	The potential role of the combined PARP-1 and VEGF inhibition in severe SARS-CoV-2 (COVID-19) infection. <i>Journal of Infection in Developing Countries</i> , 2022, 16, 101-111.	0.5	4
79	Intensive weekly chemotherapy with docetaxel, epirubicin and carboplatin with G-CSF support in patients with advanced gastric cancer. <i>Medical Oncology</i> , 2007, 24, 301-307.	1.2	3
80	Adjusting Breast Cancer Patient Prognosis with Non-HER2-Gene Patterns on Chromosome 17. <i>PLoS ONE</i> , 2014, 9, e103707.	1.1	3
81	Cyclin D1 differential activation and its prognostic impact in patients with advanced breast cancer treated with trastuzumab. <i>ESMO Open</i> , 2019, 4, e000441.	2.0	3
82	Tumor Mutational Patterns and Infiltrating Lymphocyte Density in Young and Elderly Patients With Breast Cancer. <i>Cancer Genomics and Proteomics</i> , 2020, 17, 181-193.	1.0	2
83	Impact of tumor angiogenic profile on the outcome of patients with metastatic breast carcinoma treated with weekly docetaxel. A Hellenic Cooperative Oncology Group (HeCOG) study. <i>Histology and Histopathology</i> , 2015, 30, 1129-41.	0.5	2
84	Patterns of practice and pharmacoeconomic analysis of the management of patients with metastatic renal cell carcinoma (mRCC) in Greece—the CRISIS study. A retrospective analysis by the Hellenic Genitourinary Cancer Group (HGUCG). <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2019, 19, 491-501.	0.7	1
85	Immune-related dermatologic toxicities: to make a long story short. <i>Cutaneous and Ocular Toxicology</i> , 2020, 39, 10-12.	0.5	1
86	An Observational Study to Assess the Molecular Epidemiology and Direct Medical Costs of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients with Advanced EGFR Mutation-Positive Non-Small Cell Lung Cancer Treated with Afatinib in Real-World Clinical Settings in Greece. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 93-102.	1.3	1
87	Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative. <i>Oncotarget</i> , 2020, 11, 1-14.	0.8	1
88	Irinotecan and oxaliplatin combination, as second-line treatment, in fluoropyrimidine-pretreated advanced colorectal cancer. A phase II study by the Hellenic Cooperative Oncology Group (HeCOG). <i>Tumori</i> , 2005, 91, 309-13.	0.6	1
89	Real-World Data on Treatment Management and Outcomes of Patients with Newly Diagnosed Advanced Epithelial Ovarian Cancer in Greece (The EpOCa Study). <i>Current Oncology</i> , 2021, 28, 5266-5277.	0.9	1
90	OLAPARIB: A promising PARP Inhibitor for the treatment of ovarian cancer. <i>Forum of Clinical Oncology</i> , 2015, 6, 1-7.	0.1	0